Dose-effect relationship of ropivacaine combined with 0.4ug/mLdexmedetomidine for labor analgesia

Dose-effect relationship of ropivacaine combined with 0.4ug/mL dexmedetomidine for labor analgesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059557

Enrollment

Unknown

Registered

2022-05-04

Start date

2022-06-01

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor analgesia

Interventions

Group 1:0.04% Ropivacaine

Group 2:0.06% Ropivacaine

Group 3:0.08% Ropivacaine

Group 4:0.10% Ropivacaine

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: ASA statue of I or II, patients with a single pregnancy, at full-term (gestational aged >= 37 weeks).

Exclusion criteria

Exclusion criteria: 1. Obesity (BMI>35kg/m^2); 2. Active labor preterm diabetes or gestational diabetes, hypertension or preeclampsia; 3. Intrauterine growth restriction or giant fetus, placenta previa, placenta adhesion, placenta accreta, major maternal diseases; 4. Absolute contraindications to spinal or epidural anesthesia, such as local infection or bleeding disorders.

Design outcomes

Primary

Measure	Time frame
The success rate of labor analgesia;PH of umbilical artery blood;hypotension;	—

Secondary

Measure	Time frame
Visual analogue scale score;Miyaguchi;	—

Countries

China

Contacts

Public ContactXiao Fei

13706597501@163.com+86 13706597501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026